Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc.（BCLI）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · BCLI · 截至 2025年9月30日
股东结构概览
5
机构持有人数
▼ 28 vs Q2
$1,727
机构持仓总市值
▼ $262,231 vs Q2
11.03M
总流通股
freeFloat 68.87%
2,317
13F 申报持股数
▼ 233,461 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
BCLI 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ADVISOR GROUP HOLDINGS, INC. biological products, (no diagnostic substances) | 1.8K | 2.07% | 2.07% | $1.35M | Nov 14, 2025 | — held |
BANGOR SAVINGS BANK biological products, (no diagnostic substances) | 266 | 0.31% | 0.31% | $188,000 | Oct 27, 2025 | — held |
VSM WEALTH ADVISORY, LLC biological products, (no diagnostic substances) | 120 | 0.14% | 0.14% | $85,000 | Nov 13, 2025 | — held |
STEWARD PARTNERS INVESTMENT ADVISORY, LLC biological products, (no diagnostic substances) | 113 | 0.13% | 0.13% | $80,000 | Nov 12, 2025 | — held |
ST GERMAIN D J CO INC biological products, (no diagnostic substances) | 33 | 0.04% | 0.04% | $23,000 | Oct 7, 2025 | — held |
JONES FINANCIAL COMPANIES LLLP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 4, 2025 | EXIT |
HARBOUR INVESTMENTS, INC. biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 12, 2025 | EXIT |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 7, 2025 | EXIT |
CLEARSTEAD ADVISORS, LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 10, 2025 | EXIT |
RAYMOND JAMES FINANCIAL INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
0
增持
+0 股0
新建仓
首次建仓0
减持
−0 股28
清仓
完全退出净股数变化（前50家）
+0
+0 / −0
净新增持仓人
-28
新建 0 个 / 退出 28 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
BCLI 内幕交易记录
数据来源：SEC Form 4
11
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Lebovits Chaim President & CEO | Feb 26, 2026 | Award | 1,800,000 | — | — | 2.00M | Form 4 ↗ |
Yablonka Uri EVP & Chief Business Officer | Feb 26, 2026 | Award | 150,000 | — | — | 218.5K | Form 4 ↗ |
Patlis Alla See Remarks | Feb 26, 2026 | Award | 100,000 | — | — | 144.3K | Form 4 ↗ |
FRENKEL JACOB A director | Feb 26, 2026 | Award | 200,000 | — | — | 243.8K | Form 4 ↗ |
ARBEL IRIT director | Feb 26, 2026 | Award | 120,000 | — | — | 161.1K | Form 4 ↗ |
Bairu Menghisteab director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
Polverino Anthony J. director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
HARTOUNIAN HARTOUN director | Feb 26, 2026 | Award | 225,000 | $0.70 | $157.5K | 225.0K | Form 4 ↗ |
Lindborg Stacy director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
Naor Nir director | Feb 26, 2026 | Award | 180,000 | $0.70 | $126.0K | 180.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Brainstorm Cell Therapeutics Inc.（BCLI）主要由机构投资者持有，机构持股比例约为 0.0%。公司内部人员持股约 31.13%，散户及公众持股约占剩余的 68.85%。
Brainstorm Cell Therapeutics Inc. 最大机构股东为 ADVISOR GROUP HOLDINGS, INC.，截至 September 30, 2025 持有约 1,785 股，占总流通股的 2.07%。
目前共有 5 家机构持有 BCLI 股票，合计持仓市值约 $1,727，数据来源为最新 SEC 13F 申报。
常见问题
BCLI ownershipBrainstorm Cell Therapeutics Inc.（BCLI）主要由机构投资者持有，机构持股约 0.0%。最大股东为 ADVISOR GROUP HOLDINGS, INC.，持股比例 2.07%。内部人员持股约 31.13%。数据来源 SEC Form 13F，截至 September 30, 2025。